Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence

Stephan Ehrhardt; Chan Xie; Nan Guo; Kenrad Nelson; Chloe L. Thio

doi:10.1093/cid/ciu798

Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence

Stephan Ehrhardt, Chan Xie, Nan Guo, Kenrad Nelson, Chloe L. Thio

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother to child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.

Original language	English (US)
Pages (from-to)	275-278
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	60
Issue number	2
DOIs	https://doi.org/10.1093/cid/ciu798
State	Published - Jan 15 2015

Keywords

breastfeeding
hepatitis B
lamivudine
tenofovir

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciu798

Cite this

@article{c6c5100d2e3e4602a6cd1c6dd944a61a,

title = "Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence",

abstract = "Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother to child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.",

keywords = "breastfeeding, hepatitis B, lamivudine, tenofovir",

author = "Stephan Ehrhardt and Chan Xie and Nan Guo and Kenrad Nelson and Thio, {Chloe L.}",

note = "Publisher Copyright: {\textcopyright} 2014 The Author.",

year = "2015",

month = jan,

day = "15",

doi = "10.1093/cid/ciu798",

language = "English (US)",

volume = "60",

pages = "275--278",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate

T2 - A review of the evidence

AU - Ehrhardt, Stephan

AU - Xie, Chan

AU - Guo, Nan

AU - Nelson, Kenrad

AU - Thio, Chloe L.

PY - 2015/1/15

Y1 - 2015/1/15

N2 - Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother to child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.

AB - Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother to child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.

KW - breastfeeding

KW - hepatitis B

KW - lamivudine

KW - tenofovir

UR - http://www.scopus.com/inward/record.url?scp=84924977749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924977749&partnerID=8YFLogxK

U2 - 10.1093/cid/ciu798

DO - 10.1093/cid/ciu798

M3 - Review article

C2 - 25313254

AN - SCOPUS:84924977749

SN - 1058-4838

VL - 60

SP - 275

EP - 278

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this